About Planet Biopharmaceuticals
Planet Biopharmaceuticals is a company based in Ridgefield (United States) founded in 1968 was acquired by Waypoint Capital in April 2013. Planet Biopharmaceuticals operates in a competitive market with competitors including HOOKIPA Pharma, Valneva, Stallergenes Greer, IgGenix and Immunomic Therapeutics, among others.
- Headquarter Ridgefield, United States
- SectorsHealthcare
- Website planetbiopharmaceuticals.com
- Social LinkedIn
- Acquired by Waypoint Capital (Apr 2013)
- Investors
- Acquired byWaypoint Capital
(Apr 2013)
Investors in Planet Biopharmaceuticals
Planet Biopharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include B-FLEXION.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
B-FLEXION is recognized as a private entrepreneurial investment firm. | – | waypointcapital.net | - |
Investor details for Planet Biopharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Planet Biopharmaceuticals
2 dated milestones of Planet Biopharmaceuticals across 45 years, from founding to its latest funding, stage changes and deals.
- Founded Planet Biopharmaceuticals is founded.
- Exit Acquired by Waypoint Capital.
Competitors of Planet Biopharmaceuticals
Planet Biopharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HOOKIPA Pharma, Valneva, Stallergenes Greer, IgGenix and Immunomic Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| hookipapharma.com | 2011 | Vienna, Austria | $133.72M | – | Developer of immunotherapies for the treatment of infectious diseases and cancer | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| stallergenesgreer.com | 2013 | London, United Kingdom | – | 115,499 | Allergen immunotherapies for respiratory allergies are developed. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| immunomix.com | 2005 | Rockville, United States | $104.44M | 51 | Immunomic Therapeutics is engaged in developing nucleic acid immunotherapy platforms. | |
| alk.net | 1923 | Horsholm, Denmark | – | – | Danish, Public Biopharma company developing allergy immunotherapies including injections (emergency) and sublingual tablets. | |
| paxvax.com | 2007 | San Diego, United States | $211.78M | 138 | Oral vaccines against infectious diseases such as cholera, bird flu, HIV & others. | |
| alladapt.com | 2018 | Menlo Park, United States | $179M | 1 | Therapeutics for treating food allergies are developed. |
Detailed competitors of Planet Biopharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Planet Biopharmaceuticals
10 companies that operate in the same segment as Planet Biopharmaceuticals (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Planet Biopharmaceuticals
Planet Biopharmaceuticals was founded in 1968.
Planet Biopharmaceuticals is headquartered in Ridgefield, United States.
Founded in 1968, Planet Biopharmaceuticals is based in Ridgefield, United States, within the biopharmaceutical sector. Allergenic extracts addressing allergens such as eight kinds of grass, house dust mites, cat hair, and short ragweed at 100,000 AUmL are offered. A spirometer for asthma diagnosis was added recently. Comprehensive allergenic extract options are maintained for the U.S. market, with services extended to ENT specialists over decades.
Planet Biopharmaceuticals's top competitors include HOOKIPA Pharma, Stallergenes Greer and Valneva.
Planet Biopharmaceuticals has 1 investor. Key investors include B-FLEXION.
Yes. Planet Biopharmaceuticals was acquired by Waypoint Capital in April 2013.